[HTML][HTML] 2, 4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
Despite the clinical success of Androgen Receptor (AR)-targeted therapies, reactivation of
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
2, 4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
A Blomme, CA Ford, E Mui, R Patel, C Ntala… - Nature …, 2020 - hal.science
Despite the clinical success of Androgen Receptor (AR)-targeted therapies, reactivation of
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
2, 4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
A Blomme, CA Ford, E Mui, R Patel… - Nature …, 2020 - ui.adsabs.harvard.edu
Despite the clinical success of Androgen Receptor (AR)-targeted therapies, reactivation of
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
2, 4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
A Blomme, CA Ford, E Mui, R Patel, C Ntala… - Nature …, 2020 - eprints.gla.ac.uk
Despite the clinical success of Androgen Receptor (AR)-targeted therapies, reactivation of
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
2, 4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
A Blomme, CA Ford, E Mui, R Patel… - Nature …, 2020 - inserm.hal.science
Despite the clinical success of Androgen Receptor (AR)-targeted therapies, reactivation of
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
2, 4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
A Blomme, CA Ford, E Mui, R Patel, C Ntala… - Nature …, 2020 - inria.hal.science
Despite the clinical success of Androgen Receptor (AR)-targeted therapies, reactivation of
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
2, 4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
A Blomme, CA Ford, E Mui, R Patel… - Nature …, 2020 - strathprints.strath.ac.uk
Despite the clinical success of Androgen Receptor (AR)-targeted therapies, reactivation of
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
2, 4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
A Blomme, CA Ford, E Mui, R Patel, C Ntala… - Nature …, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Despite the clinical success of Androgen
Receptor (AR)-targeted therapies, reactivation of AR signalling remains the main driver of …
Receptor (AR)-targeted therapies, reactivation of AR signalling remains the main driver of …
[PDF][PDF] 2, 4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
A Blomme, CA Ford, E Mui, R Patel, C Ntala… - core.ac.uk
Results ARI-resistant cells display altered but active AR signalling. To study resistance to AR
inhibition, we characterised CRPC derivatives of LNCaP cells that were chronically cultured …
inhibition, we characterised CRPC derivatives of LNCaP cells that were chronically cultured …
2, 4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer.
A Blomme, CA Ford, E Mui, R Patel… - Nature …, 2020 - search.ebscohost.com
Despite the clinical success of Androgen Receptor (AR)-targeted therapies, reactivation of
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …